Home - Products - Others - Other Targets - Cyanidin-3-O-sambubioside-5-O-glucoside chloride

Cyanidin-3-O-sambubioside-5-O-glucoside chloride

CAS No. 53925-33-0

Cyanidin-3-O-sambubioside-5-O-glucoside chloride( —— )

Catalog No. M32004 CAS No. 53925-33-0

Cyanidin-3-O-sambubioside-5-O-glucoside chloride is a natural product for research related to life sciences.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 628 In Stock
50MG Get Quote In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Cyanidin-3-O-sambubioside-5-O-glucoside chloride
  • Note
    Research use only, not for human use.
  • Brief Description
    Cyanidin-3-O-sambubioside-5-O-glucoside chloride is a natural product for research related to life sciences.
  • Description
    Cyanidin-3-O-sambubioside-5-O-glucoside chloride is a natural product for research related to life sciences.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    ——
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    53925-33-0
  • Formula Weight
    779.1
  • Molecular Formula
    C32H39ClO20
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • Neoprocurcumenol

    Neoprocurcumenol is a larvicidal compound that exerts significant toxicity on mosquito larvae with LC50 and LC 90 values of 13.69 and 23.92 ppm, respectively.

  • Neuropeptide Y (porc...

    Neuropeptide Y, porcine, a peptide in porcine brain, is capable of inhibiting secretin-stimulated pancreatic secretion.

  • SPR741

    SPR741, formerly NAB741 (12), is a cationic peptide derived from polymyxin B and is one such potentiator molecule that is under development for the treatment of serious Gram-negative bacterial infections.